CONTACT US
If you have any questions or concerns about this AACR conference, please contact the AACR Program Development Department at (215) 440-9300 or
programs@aacr.org.
ASSISTANCE FOR PHYSICALLY CHALLENGED REGISTRANTS
The AACR makes its meetings accessible to all attendees. Registrants with special requirements for transportation, hotel accommodations, or other facilities connected with the meeting should notify the AACR in advance by checking the appropriate box on the registration form or by contacting the AACR Meetings Department at (215) 440-9300 or
meetings@aacr.org. A list of organizations in Philadelphia that offer special equipment or services for the physically challenged will be posted on this page as the meeting approaches. Please note that the box on the registration form is only for physically challenged registrants.
OPPORTUNITIES FOR SURVIVOR AND PATIENT ADVOCATE INVOLVEMENT
The AACR strongly encourages the involvement of survivors and patient advocates in this conference. For more details, please contact the AACR Department of Survivor and Patient Advocacy at
advocacy@aacr.org or (215) 440-9300 x 240.
PROFESSIONAL ADVANCEMENT SESSION FOR YOUNG INVESTIGATORS
This year's conference will again feature a Professional Advancement Session specifically designed for early-career investigators. During this informal session, participants will be able to assess their career goals, discuss scientific issues, exchange ideas, and network with others working in these fields. This is an invaluable opportunity to receive guidance and insight from senior-level scientists about the opportunities and challenges in these areas of science and cancer medicine.
This always popular session will take place on Wednesday, September 24 from 1:00 p.m. to 2:15 p.m. in the Philadelphia Marriott Downtown. We encourage all registered predoctoral students, medical students, post-doctoral fellows, and physicians-in-training to attend. Lunch will be provided and space is limited.
To participate in this event, please contact Natalie Konrad at (215) 440-9300 or natalie.konrad@aacr.org.
PROGRAM COMMITTEE
CHAIRPERSON
Gordon B. Mills, UT M. D. Anderson Cancer Center, Houston, TX
CO-CHAIRPERSONS
Laura J. van’t Veer, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Barbara L. Weber, GlaxoSmithKline, King of Prussia, PA
SCIENTIFIC PROGRAM COMMITTEE
J. Carl Barrett, Novartis Institute for Biomedical Research, Inc., Cambridge, MA
Wafik S. El-Deiry, University of Pennsylvania, Philadelphia, PA
Gary B. Gordon, Abbott Labs, Abbott Park, IL
Steven I. Gutman, Food and Drug Administration, Rockville, MD
Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
Edison T. Liu, Genome Institute of Singapore, Singapore
Sanford D. Markowitz, Case Western Reserve University, Cleveland, OH
Jane Perlmutter, Gemini Group, Naperville, IL
Mark J. Ratain, University of Chicago, Chicago, IL
Michael K. Samoszuk, Roche Diagnostics Corporation, Indianapolis, IN
Thea D. Tlsty, UCSF School of Medicine, San Francisco, CA
David A. Tuveson, CRUK Cambridge Research Institute, Cambridge, UK
Paul M. Waring, Genentech, Inc., South San Francisco, CA
SCIENTIFIC REVIEW COMMITTEE
Alex A. Adjei , Roswell Park Cancer Institute, Buffalo, NY
Maher Albitar, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA
Kerry L. Blanchard, Eli Lilly and Company, Indianapolis, IN
James D. Brenton, Cancer Research UK, Cambridge Research Institute, Cambridge, England
Andrea Califano, Columbia University, New York, NY
George A. Calin, UT M. D. Anderson Cancer Center, Houston, TX
Richard M. Caprioli, Vanderbilt University, Nashville, TN
Esther H. Chang, Lombardi Comp. Cancer Center at Georgetown University, Washington, DC
Pamela S. Cohen, Kosan Biosciences, Inc., Hayward, CA
Caroline Dive, Paterson Institute for Cancer Research, Manchester, England
Mauro Ferrari, UT Health Science Center, Houston, TX
Shrin K. Ford, Bristol-Myers Squibb, Pennington, NJ
Susan M. Galbraith, Bristol-Myers Squibb Company, Princeton, NJ
Holly H. Gallion, Precision Therapeutics, Pittsburgh, PA
Joanna L. Groden, The Ohio State University College of Medicine, Columbus, OH
Adrian L. Harris, Weatherall Institute of Molecular Medicine, Oxford, England
Monika E. Hegi, University Hospital, Lausanne, Switzerland
Peter J. Houghton, St. Jude Children's Research Hospital, Memphis, TN
Pearl S. Huang, Merck & Co., Inc., North Wales, PA
Kazuto Nishio, Kinki University School of Medicine, Osaka , Japan
Akhilesh Pandey, Johns Hopkins University, Baltimore, MD
Scott D. Patterson, Amgen, Thousand Oaks, CA
David Piwnica-Worms, Washington University School of Medicine, St. Louis, MO
Robert Radinsky, Amgen, Inc., Thousand Oaks, CA
Mary V. Relling, St. Jude Children's Research Hospital, Memphis, TN
Eric Keith Rowinsky, ImClone Systems Incorporated, Branchburg, NJ
Daniel J. Sargent, Mayo Clinic College of Medicine, Rochester, MN
Judith S. Sebolt-Leopold, JS Leopold Consulting, Ann Arbor, MI